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In Brief
High levels of triglyceride-rich
lipoproteins have been implicated in the
pathogenesis of cardiovascular
complications. Saja et al. demonstrate
that hypertriglyceridemia promotes
extravasation of Gr1low monocytes and
accumulation of tissue macrophages.
Hypertriglyceridemia was associated
with increased levels of CCL4, which
contributes to the migration of Gr1low
monocytes.
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Monocytes are heterogeneous effector cells involved
in themaintenance and restoration of tissue integrity.
However, their response to hyperlipidemia remains
poorly understood. Here, we report that in the pres-
ence of elevated levels of triglyceride-rich lipopro-
teins, induced by administration of poloxamer 407,
the blood numbers of non-classical Ly6C/Gr1low
monocytes drop, while the number of bone marrow
progenitors remains similar. We observed an
increased crawling and retention of the Gr1low mono-
cytes at the endothelial interface and a marked
accumulation of CD68+ macrophages in several
organs. Hypertriglyceridemia was accompanied by
an increased expression of tissue, and plasma
CCL4 and blood Gr1low monocyte depletion involved
a pertussis-toxin-sensitive receptor axis. Collec-
tively, these findings demonstrate that a triglycer-
ide-rich environment can alter blood monocyte
distribution, promoting the extravasation of Gr1low
cells. The behavior of these cells in response to dys-
lipidemia highlights the significant impact that high
levels of triglyceride-rich lipoproteins may have on
innate immune cells.INTRODUCTION
Marked elevations in triglyceride-rich lipoprotein (TGRL) levels
are observed in individuals with rare genetic disorders such as
familial lipoprotein lipase deficiency (Benlian et al., 1996) and
when a common genetic disorder occurs in association with an
acquired secondary form of hypertriglyceridemia such as dia-
betes or alcohol consumption (Pejic and Lee, 2006). Further-
more, abnormalities in TGRL levels are commonly observed in1802 Cell Reports 12, 1802–1815, September 22, 2015 ª2015 The Apatients with persistent infections like HIV (Oh and Hegele,
2007) or chronic inflammatory conditions such as systemic lupus
erythematosus (SLE) (Bruce, 2005). Although elevated TGRL
levels are thought to contribute to the increased risk of cardio-
vascular complications observed in all these conditions (Benlian
et al., 1996; Bruce, 2005), the pathogenic impact of an abnormal
TGRL profile remains poorly understood.
Themononuclear phagocyte system (MPS) plays a central role
in the maintenance of tissue integrity. In a hyperlipidemic envi-
ronment, cells of the MPS ingest excess lipids that activate
them through a variety of signaling pathways, leading to
increased secretion of pro-inflammatory cytokines and eventu-
ally cell death (Moore and Tabas, 2011). The notion of toxic
and inflammatory effects of lipid metabolites has been sup-
ported by an extensive literature using murine models of
hyperlipidemia such as strains genetically deficient in either the
low-density lipoprotein receptor (LDLR) or apolipoprotein E
(ApoE). These models replicate human hypercholesterolemic
states and the associated inflammatory response, but they do
not recapitulate triglyceride-rich dyslipidemia. Moreover, the
nature of the lipid responsible for theMPS responses in hyperlip-
idemia remains unresolved; both inflammatory and anti-inflam-
matory effects have been attributed to cholesterol (Spann and
Glass, 2013). Finally, the MPS cell type responding to hyperlipid-
emia remains poorly understood. Most work has focused on
dendritic cells and tissue macrophages, while much less atten-
tion has been given to blood monocytes. However, reports of
postprandial activation of monocytes from acute changes in
TGRLs (Gower et al., 2011) suggest that these cells may be
important in the handling of circulating lipids.
Monocytes, identified as CD11b+CD115+ cells, are a hetero-
geneous population of blood leukocytes with phagocytic and
immunomodulatory properties. At least two phenotypically and
functionally distinct monocyte subsets have been described in
humans, rats, pigs, and mice (Geissmann et al., 2003; Yona
and Jung, 2010; Ziegler-Heitbrock, 2014), indicating evolu-
tionary conservation. The murine monocyte subpopulations
have been termed ‘‘classical’’ and ‘‘non-classical’’ based onuthors
differences in surface markers and functional properties. The
classical monocytes express lower levels of CX3CR1 and higher
levels of the C-C chemokine receptor 2 (CCR2) and lymphocyte
antigen 6c (Ly6C) (or the myeloid differentiation antigen Gr1) and
are defined as CX3CR1intCCR2highGr1high (abbreviated as
Gr1high). They are considered to be equivalent to CD14high hu-
man monocytes (Cros et al., 2010). The Gr1high cells represent
the inflammatory monocyte subtype and are actively recruited
to inflamed tissue, where they may give rise to macrophages.
Their behavior appears to be distinct from the second blood
monocyte subpopulation, identified as CX3CR1highCCR2low
Gr1low (abbreviated as Gr1low). The equivalent cells in humans
are identified as CD14lowCD16high (Cros et al., 2010). The Gr1low
monocytes have been shown to patrol the luminal surface of
endothelial cells, acting as ‘‘housekeepers’’ of the vasculature
(Auffray et al., 2007; Carlin et al., 2013b). Their migratory proper-
ties remain elusive, and the possibility they may sense and
respond to different environmental stimuli in the absence of
inflammation is unexplored.
Given the fact that in steady-state conditions, monocytes do
not contribute to themaintenance ofmost peripheral tissuemac-
rophages (Hashimoto et al., 2013; Yona et al., 2013) but are
exposed to changes in plasma lipids, their behavior during hyper-
lipidemia requires investigation. Here, we report that a hyper-
TGRL environment promotes differential migration of blood
monocytes. Hyper-TGRL induced Gr1low monocytes to extrava-
sate into surrounding tissue. This process was associated with
increased CCL4 levels and was partially dependent on a
pertussis toxin (PT)-sensitive receptor axis. Our findings indicate
that Gr1low monocytes, in addition to patrolling the endothelial
luminal surface (Auffray et al., 2007; Carlin et al., 2013b), are likely
to have an extravascular role under hyper-TGRL conditions.
RESULTS
Elevated TGRL Levels Alter Blood Monocyte Subset
Distribution
To mimic the increased TGRL levels observed in many patients
with metabolic disorders, we used the poloxamer 407 (P-407)-
inducedmodel of dyslipidemia (Johnston, 2004). This chemically
induced model of hyperlipidemia involves the intraperitoneal
(i.p.) administration of the non-ionic surfactant P-407 to wild-
type C57BL/6 (B6) mice on chow diet and allows for a dose-
controlled dyslipidemia. We first established the dosing regimen
that resulted in a stable increase in TGRL levels. As previously re-
ported (Johnston, 2004), we found that administration of P-407
(0.5 g/kg every second day) to B6 mice for 28 days resulted in
an average plasma triglyceride (TG) concentration of 2,691.2 ±
501.8 mg/dl compared with 80.2 ± 6.26 mg/dl in PBS-treated
controls and a modest increase in plasma cholesterol (CHOL)
(324 ± 37.1 mg/dl in P-407-treated mice versus 106.2 ±
3.27 mg/dl in PBS-treated mice [mean ± SEM]) (Figures S1A–
S1D). Chromatography showed that in P-407-treated animals,
all of the TG was associated with the VLDL fraction (Figures
S1E and S1F), consisting mainly of Apo-E and apolipoprotein
C-III (APOC3) (Figure S1G). Importantly, the P-407-induced dys-
lipidemia did not trigger an overt inflammatory response (Fig-
ure S1H). The body weight of the P-407-injected animals didCell Repnot change (Figure S1I) and no evidence of renal damage was
detected as judged by the absence of hematuria and albuminuria
(data not shown). As previously reported (Johnston et al., 1993),
there was a mild splenomegaly in the P-407-treated group when
compared to controls (Figure S1J). Histological analysis after
4-week treatment showed some cells with a characteristic
foamy cytoplasm in the spleen, liver, and heart (Figure S1K), indi-
cating increased tissue lipid load and foam cell formation.
Diet-induced hypercholesterolemia in ApoE-deficient mice
has been shown to induce monocytosis associated mainly with
a shift toward an increased frequency of the Gr1high subset
compared with Gr1low fraction (Swirski et al., 2007; Tacke
et al., 2007). The increase in TGRLs induced by P-407 treatment
did not alter the total number of bloodmonocytes (Figure 1A), but
the distribution of the two major monocyte subsets showed a
different pattern (Figure 1B). We observed a progressive and
marked drop in the numbers of Gr1low monocytes starting as
early as 7 days post-P-407 injections with a relatively modest in-
crease in the number of Gr1high monocytes (Figures 1C and 1D).
At the end point, the P-407-treated mice had dropped their
Gr1low monocyte numbers to less than half compared to the
starting point (p < 0.0001), while the number of Gr1high mono-
cytes was not significantly different (p = 0.25). In contrast, other
peripheral blood cells (total white cell, B and T cells, and
polymorphonuclear leukocytes) did not show consistent or
reproducible changes in their numbers or frequencies (Figures
S2A–S2H). The drop in circulating Gr1low monocytes under the
P-407 treatment could not be explained by a selective toxic
effect of the dyslipidemia as the percentages of the Annexin
V+/PI+ monocytes were not markedly different between the
two monocyte subpopulations, irrespective of the treatment
(Figure 1E). Additionally, in vitro exposure of peripheral blood
mononuclear cells (PBMCs) to P-407 concentrations ranging
from 50 mg/ml to 10 mg/ml did not affect the survival of the cells
(Figure S2I). We then investigated a model of diet-dependent
hyperlipidemia using the LDLR-deficient (Ldlr/) mice that
develop hypercholesterolemia and a modest hypertriglyceride-
mia on a high-fat (HF) diet (Figures S2J and S2K). Animals
were euthanized after 50 days on the diet, an age at which
Ldlr/ mice do not develop advanced atherosclerotic lesions
(Ma et al., 2012) or monocytosis (Murphy et al., 2011) (Fig-
ure S2L). Under these conditions, we observed significantly
fewer Gr1low monocytes in the Ldlr/ mice kept on an HF diet
compared to those maintained on a chow diet (Figures S2M
and S2N), indicating that the changes in monocyte subsets in
P-407-treated animals were the result of the dyslipidemia and
not an adverse effect of P-407.
Consistent with the inhibitory effect of P-407 on the capillary
endothelial lipoprotein lipase (Johnston, 2004), a known medi-
ator of TG hydrolysis, we also found that P-407 did not induce
accumulation of neutral lipid content in leukocytes (Figures 1F
and 1G). On the contrary, there was a trend toward a decreased
amount of lipid in the blood cells of the P-407-treated animals.
Taken together these data indicate that the increase in TGRLs
modulates the steady-state distribution of the blood monocyte
subsets without altering other leukocytes. We then explored
whether the changes triggered by the P-407 treatment occurred
in the bone marrow (BM) or in the periphery.orts 12, 1802–1815, September 22, 2015 ª2015 The Authors 1803
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Figure 1. Characterization of Blood Monocytes in P-407-Treated Mice
(A) Quantitative analysis of total monocyte numbers in B6mice treated with P-407 or PBS for 28 days. Circulatingmonocytes were identified by their low SSC and
co-expression of CD115 and CD11b.
(B) Representative dot plots showing the frequencies of Gr1high and Gr1low monocyte subsets at the end of the time course.
(C and D) Numbers (C) and relative frequencies (D) of Gr1low and Gr1high blood monocytes. P-407-treated mice kept on a chow diet had significantly fewer
Gr1low and more Gr1high monocytes at each time point. Plots represent data pooled from four different experiments and show the mean values ± SE for
at least seven mice per time point. The p value of the comparison between day 0 and day 28 is indicated (*p < 0.05; **p < 0.01, and ***p < 0.001; unpaired
t test).
(E) Frequency of Annexin V+/PI+ monocytes in the twomonocyte subpopulations 7 and 14 days after P-407 treatment. Results are expressed asmean ± SE, n = 4
per time point (unpaired t test).
(legend continued on next page)
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The P-407-Induced Dyslipidemic Environment Does Not
Affect the Generation of Gr1low Monocytes
We first examined the frequency of the BM-resident founder
cells termed common monocyte progenitor (cMoP) (Hettinger
et al., 2013). The analysis of the BM at 2 and 4 weeks failed to
show any significant difference between the two experimental
groups in the numbers of cMoPs, total monocytes, and mono-
cyte subpopulations (Figures 2A–2D), demonstrating that the
drop in Gr1low monocytes could not be the result of an impaired
production in the BM. As the spleen can contribute to the clear-
ance of apoptotic monocytes (Getts et al., 2014) and at the same
time act as a ‘‘reservoir’’ for the Gr1high monocytes (Swirski et al.,
2009), we assessed the effect of splenectomy on the monocyte
distribution. Splenectomized mice treated with P-407 still had a
drop in the percentage and number of Gr1low monocytes when
compared to the PBS-treated group (Figures 2E and S3A), con-
firming that P-407 did not promote the splenic clearance of
apoptotic Gr1low monocytes (see also Figure 1E).
Gr1high monocytes have been shown to be the precursors of
the steady-state Gr1low cells (Tacke et al., 2006; Yona et al.,
2013). Therefore, we used a 5-bromo-20-deoxyuridine (BrdU)
pulsing regimen to investigate whether the elevated TGRLs pre-
vented Gr1high > Gr1low conversion or increased the half-life of
Gr1high blood monocytes. Mice were pulsed with three i.p. injec-
tions of 2 mg BrdU (3 hr apart), and treatment with P-407 or PBS
was started on the same day. As shown in Figures 2F and S3B,
the BrdU incorporation into the two monocyte subsets was
tracked over a period of 5 days. By day 1, the vast majority of
BrdU+ monocytes were Gr1high (Figure 2F, left panel). This
continued for 3 days when a significant drop of the BrdU+ mono-
cytes was noted in both experimental groups, indicating that the
dyslipidemic environment had not altered the half-life of the
Gr1high subset and thus this could not be the explanation for
the drop in theGr1low compartment. A small fraction of theGr1low
subset showed BrdU staining by day 1, and this gradually
increased over 5 days in the PBS-treated group (Figure 2F, right
panel), confirming the delayed BrdU incorporation into theGr1low
compartment (Yona et al., 2013). The kinetic of the BrdU incor-
poration in the Gr1low fraction differed slightly in the P-407-
treated mice and the expected increase at day 5 was not
observed (Figure 2F, right panel), suggesting the possibility of
a different steady-state behavior of this monocyte compartment
in the dyslipidemic environment. To investigate this, we studied
effects of elevated TGRLs on the mobility of Gr1low monocytes
in vivo.
Increased TGRL Levels Promote CX3CR1high Monocyte
Crawling and Tissue Accumulation of CD68+
Macrophages
Gr1low monocytes are thought to monitor endothelial integrity
(Auffray et al., 2007; Carlin et al., 2013b). To examine the effect
of the P-407-induced hyper-TGRL environment on the Gr1low(F) Representative images of neutral lipid content in blood leukocytes after 28
accumulation using the LipidTox kit according to manufacturer’s instructions. Ne
(G) Quantification of the lipid content. Data are expressed asmean fluorescent inte
per group; unpaired t test). Horizontal bars represent means. ns, nonsignificant.
See also Figures S1 and S2.
Cell Repmonocytes at the endothelial interface, we used the Cx3cr1gfp
reporter mouse strain. This has been widely used to discriminate
the two monocyte subpopulations (Geissmann et al., 2003) and
enables Gr1lowCX3CR1high monocytes to be tracked in situ by
intravital microscopy (Auffray et al., 2007; Cros et al., 2010).
Analysis of monocyte behavior in vivo showed that the number
of intravascular crawling GFP+ cells per hour in the ear dermis
was higher in the mice treated with P-407 for 7 days compared
to the PBS counterparts (Figures 3A and 3B; Movies S1 and
S2). Analysis of the intravital images revealed an increased accu-
mulation of extravascular GFP+ cells with amigratory behavior in
the P-407-treated animals (Figures 3A and S4A). We then per-
formed in situ experiments in the mesentery of Cx3cr1gfp/gfp
andCx3cr1gfp/+ mice (Figures 3C–3E) and found a marked accu-
mulation of GFP+ cells at the endothelial interface over 1 hr in
P-407-treated Cx3cr1gfp/+ and Cx3cr1gfp/gfp mice (Figure 3C;
Movies S3 and S4). This was accompanied by decreased veloc-
ity and track displacement (Figure 3C), both indicators of
enhanced dwell time and endothelial retention. In addition, we
observed again a significant increase in tissue (extravascular)
GFP+ cells with a migratory behavior (Figures 3D, 3E, and
S4B). Since there was no difference between Cx3cr1gfp/+ and
Cx3cr1gfp/gfp mice, this implies that under our hyper-TGRL con-
ditions, the Gr1low monocytes had acquired the ability to extrav-
asate independently of CX3CL1 signaling.
To extend the intravital microscopy findings to other organs,
we then stained liver, heart, and kidney with an antibody against
CD68, a widely used marker for tissue macrophages. The immu-
nohistochemical quantification at different time points revealed a
striking and gradually increasing accumulation of CD68+ cells in
the P-407-injected animals compared to the PBS-treated con-
trols (Figures 4A and 4B). F4/80 staining of the liver confirmed
the increased presence of macrophages (Figure S4C). In agree-
ment with the intravital findings, the number of CD68+ cells was
already significantly increased 1 week after P-407 injections.
As recent papers have highlighted the self-renewal properties
of tissue macrophages (Epelman et al., 2014), we used Ki-67, a
well-known marker of proliferation, and found no evidence
of proliferation (Figure 4C). Collectively, these data indicated
that the drop in Gr1low bloodmonocytes under hyper-TGRL con-
ditions could be due to increased extravasation and tissue
accumulation.
Gr1low Monocytes Are Recruited into Tissues under
Increased TGRL Conditions
To formally demonstrate that Gr1low monocytes were indeed
trafficking into the organs in the P-407-treated mice, we per-
formed BM transplant and adoptive transfer experiments using
the Cx3cr1gfp/gfp mice. Two months after the engraftment of
theCx3cr1gfp/gfp BM cells into B6 recipients, we detected a large
number of GFP+ cells in all the organs prior to any P-407 inter-
vention (Figure S4D), probably as a result of the damage causeddays of PBS or P-407 treatment. Leukocytes were stained for neutral lipid
utral lipid droplets are shown in green. Scale bar, 10 mm.
nsity (MFI) per cell (mean of three fields per mouse, 15 cells/field, and four mice
orts 12, 1802–1815, September 22, 2015 ª2015 The Authors 1805
Day 14 Day 28
0
5
10
15
ns
ns
G
r1
hi
gh
m
on
oc
yt
es
(x
10
5  
ce
lls
/le
g)
Day 14 Day 28
0
5
10
15
ns
ns
P-407
PBS
M
on
oc
yt
es
(x
10
5  
ce
lls
/le
g)
E
A B
C D
Day 14 Day 28
0.0
0.5
1.0
1.5
ns ns
G
r1
lo
w
m
on
oc
yt
es
(x
10
5
ce
lls
/le
g)
0 1 2 3 4 5
0
20
40
60
80
100
ns
ns
ns
Days after BrdU injection
%
 B
rd
U
+  c
el
ls
(g
at
ed
 o
n 
G
r1
hi
gh
m
on
oc
yt
es
)
0 1 2 3 4 5
0
10
20
30
40
ns
ns
ns
P-407
PBS
Days after BrdU injection
%
 B
rd
U
+  c
el
ls
(g
at
ed
 o
n 
G
r1
low
m
on
oc
yt
es
)
F
no splenectomy splenectomy
0
25
50
75
100 * ***
*
%
G
r1
hi
gh
(g
at
ed
 o
n 
m
on
oc
yt
es
)
no splenectomy splenectomy
0
25
50
75 * ***
*
%
G
r1
lo
w
(g
at
ed
 o
n 
m
on
cy
te
s)
Day 14 Day 28
0
1
2
3
ns ns
cM
oP
(x
10
5  
ce
lls
/le
g)
Figure 2. Modulation of BM and Blood Monocyte Dynamics in P-407-Treated Mice
(A–D) Quantitative analysis of cMoPs (A), monocytes (B), and Gr1high (C) and Gr1low monocytes (D) in the BM after 14 and 28 days of P-407 or PBS treatment.
Results are expressed as mean ± SE, n = 4 per time point. p values are indicated (unpaired t test); ns, nonsignificant.
(E) Frequencies of Gr1high and Gr1low monocyte subsets after splenectomy in mice treated with PBS or P-407 for 14 days. Results are expressed as mean ± SE,
n = 4. *p < 0.05 and ***p < 0.001 (unpaired t test).
(legend continued on next page)
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by irradiation and repopulation of tissue resident macrophages
from BM progenitors (Hashimoto et al., 2013), and thus, we
abandoned this approach. We next adoptively transferred
Gr1lowGFPhigh or Gr1highGFPlow monocytes, isolated from
CD45.2Cx3cr1gfp/gfp mice, into CD45.1B6 animals pretreated
with either P-407 or PBS for 2 weeks. Recipients were sacrificed
16 hr after the adoptive transfer. To exclude the contamination
fromcirculatingmonocytes, we also injected an anti-CD11b anti-
body that labeled blood monocytes immediately prior to the
perfusion of the organs. Adoptively transferred Gr1lowGFPhigh
monocytes were detected in the liver, spleen, and kidney of
P-407-treated animals to a much greater extent than in the
PBS-treated recipients (Figures 5A and 5B). There was no
obvious recruitment in the heart, possible because of different
kinetics of macrophage accumulation (Figure 5B). Of note, we
found no increase of Gr1highGFPlow monocytes in the P-407-
treated organs (Figures 5A and 5B), corroborating our earlier
assumption that it was mainly the Gr1low subpopulation that
had extravasated in the tissues in response to the hyper-TGRL
environment. Furthermore, Gr1lowGFPhigh monocytes isolated
from P-407-treated CD45.2Cx3cr1gfp/gfp mice did not extrava-
sate when adoptively transferred into PBS-treated recipients
(Figure S5A). The monocyte expression of CD11b, CCR2,
CD68, LFA-1, and CCR5 (Figures S5B–S5F) did not change in
response to the P-407 treatment, demonstrating that neither
the P-407-induced hyper-TGRL environment nor the compound
itself had altered the phenotype of the monocytes. To determine
if the TGRL-induced drop in the number of Gr1low monocytes
was a reversible process, we treatedmicewith P-407 for 2weeks
and then stopped the treatment. On stopping the P-407 admin-
istration, lipid levels returned to normal by 72 hr (see Figure S1)
and the Gr1low fraction returned to pre-treatment levels by
2 weeks (Figure 5C).
To investigate themechanism(s) of the extravasation we quan-
tified tissue mRNA expression of a large panel of chemokines/
cytokines. As shown in Figure 6, this analysis showed a marked
upregulation of CCL4 in the organs from the P-407-treated ani-
mals compared to those from the PBS controls. CCL2 and
CCL3 also showed some increased expression. Of note, IL-6
mRNA expression showed a very different pattern and was
reduced in the liver from P-407-treated animals (Figure 6D), con-
firming that the P-407 treatment did not elicit an overt inflamma-
tory response. In keeping with the intravital data, the expression
of CX3CL1 (fractalkine) was not affected by the P-407 treatment
(Figure S6A). Similarly, other chemokines such as CXCL9,
CXCL1, and CCL5 were expressed at similar levels in the two
experimental groups (Figures S6B–S6D). As macrophages can
produce a large amount of CCL4 (Maurer and von Stebut,
2004) and were increased in tissues following P-407 treatment,
we hypothesized that they could represent a potential source
of the CCL4. We therefore analyzed CCL4 mRNA expression in
sorted CD45+F4/80+ tissue macrophages after 2 weeks of PBS
or P-407 treatment. We found that macrophages from heart(F) Percentage of BrdU incorporation into Gr1high (left panel) and Gr1low (right
administered i.p. in three doses of 2 mg, 3 hr apart. Data are representative of two
group (unpaired t test); ns, nonsignificant.
See also Figure S3.
Cell Repand liver of P-407-treated animals had a more than 2-fold in-
crease in CCL4 expression compared to those fromPBS-treated
controls (Figure 6E). We observed only a slight increase in
CCL2 expression in the liver macrophages from P-407-treated
mice (Figure 6E). We then measured CCL2 and CCL4 plasma
levels. In keeping with the gene expression data, we detected
CCL4 only in the animals treated with P-407 and not in the
PBS controls (Figure 6F), demonstrating that a hyper-TGRL
environment could induce the production of this chemokine.
We also detected an increase in CCL2 levels in the P-407
mice, but the increase reached statistical significance only at
day 14 (Figure 6F).
CCR5, which binds CCL4 and CCL3, was not selectively ex-
pressed in Gr1low monocytes, regardless of the lipid levels
(Figure S5F), making it an improbable candidate. Moreover,
CX3CR1 expression in both monocyte subsets was lower
following P-407 treatment, confirming that CX3CL1 signaling
was not driving the extravasation (Figure S5G). To support the
idea that a chemokine/chemokine receptor axis may contribute
to the migration of Gr1low monocytes into the peripheral tissue
in P-407-treated mice, we assessed whether the drop in the
Gr1low compartment could be rectified by PT, a potent inhibitor
of Gai-coupled receptor signaling, including chemokine recep-
tors. A single administration of PT after 10 days of P-407 treat-
ment prevented further extravasation of the Gr1low monocytes,
and the percentage of Gr1low monocytes increased to levels
similar to those in PBS-treated mice (Figure 6G). Additionally,
transwell chemotaxis assays with fluorescence-activated cell-
sorted Gr1low or Gr1high monocytes and recombinant mouse
CCL4 confirmed that CCL4 preferentially induces migration of
Gr1lowmonocytes (Figure 6H), while CCL2 inducesmainlymigra-
tion of Gr1high (Figure S6E). Collectively, these findings suggest
that elevated levels of TGRLs are capable of promoting a differ-
ential migration of blood Gr1low monocytes into the tissue that is
likely to be mediated, at least in part, by CCL4.
DISCUSSION
In this study, we show that increased levels of TGRLs promote
the migration of Gr1low monocytes from the blood compartment
into the surrounding tissue. The drop in the blood Gr1low subset
was accompanied by an increased crawling of these monocytes
at the endothelial interface and a striking accumulation of CD68+
tissue macrophages in the heart, liver, and kidney. The changes
in the monocyte subset distribution were not driven by systemic
inflammation but weremediated, at least in part, by chemokines,
mainly CCL4, via G-protein-coupled receptor(s).
While the cardiovascular disease (CVD) risks associated with
increased levels of cholesterol-enriched lipoproteins, in partic-
ular low-density lipoprotein (LDL), are well known and have
been extensively studied, the health-related consequences
of elevated levels of TGRLs such as very low-density lipo-
protein (VLDL) have been less well characterized and remainpanel) monocytes over a period of 5 days following a single pulse of BrdU
independent experiments. Results are expressed as mean ± SE, n = 3 in each
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Figure 3. In Vivo Behavior of CX3CR1high Monocytes under P-407-Induced Dyslipidemia
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(A) Examples of intravascular crawling cells (blue arrow) or tissue cells (white arrow) with PBS or P-407 treatment. Scale bars, 50 mm.
(B) Quantitative representation of the number of intravascular crawling cells per hour, crawling velocity and track displacement after each treatment. n = 3 per
group. ***p < 0.001 from PBS control. ns, nonsignificant. Scale bars, 50 mm.
(C) Same as (A) and (B) except that representativemesentery vasculature fromCx3cr1gfp/gfp orCx3cr1gfp/+ mice were imaged over 60min. Region of interest (ROI)
was selected which demonstrates gallery over time of CX3CR1high cell accumulation at the endothelial interface (dotted line) following P-407 treatment.
Representative of four mice; **p < 0.01. Scale bar, 50 mm.
(D and E) As in (C), where (D) shows examples of tissue from an ROI (500 mm2) away from the venule showing accumulation of tissue GFP+ cells after P-407
treatment. Two mice representative of four. Scale bar, 100 mm. (E) Quantitative representation of the number of tissue GFP+ cells in PBS- and P-407-treated
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See also Figure S4.
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controversial (Sarwar et al., 2007). Increased TGRL levels are a
key feature of the metabolic syndrome (Ninomiya et al., 2004)
and may contribute to the associated morbidity. In addition,
high TGRL levels are increasingly recognized as an independent
risk factor for CVD. To investigate the impact of a hyper-TGRL
environment, we used a murine model of P-407-induced hy-
per-TGRL (Johnston, 2004). We considered that the P-407
model was informative as (1) it induces a predominant increase
in plasma TGRL, reaching levels similar to those detected in pa-
tients with familial hypertriglyceridemia or other genetic disor-
ders of the triglyceride metabolism (Benlian et al., 1996; Pejic
and Lee, 2006); (2) there is no overt inflammatory response, a
confounding factor in other model of murine hyperlipidemia
(Getz and Reardon, 2006); and (3) P-407 did not induce monocy-
tosis or changes in monocyte surface phenotype, as previously
reported in Ldlr/ or ApoE/ mice (Swirski et al., 2007; Tacke
et al., 2007; Wu et al., 2009) and in human monocytes after a
lipid-rich meal (Foster et al., 2013; Gower et al., 2011). Using
the P-407 model, we demonstrated the migration of non-clas-
sical Gr1low monocytes into surrounding tissues.
The relationship between blood monocytes and tissue macro-
phages remains enigmatic. There is evidence that, under
steady-state conditions, monocytes are restricted to the blood
compartment and adult tissue macrophages are embryonic in
origin (Ginhoux and Jung, 2014). However, in certain tissue com-
partments, such as the skin and most notably the gut (Jaensson
et al., 2008; Bain et al., 2014), there are experimental data indi-
cating that circulating monocytes contribute significantly to the
tissue macrophage compartment. These diverse findings sug-
gest that blood monocyte migration to tissue compartments is
influenced by environmental and cell-specific factors. The ma-
jority of the work has focused on the classical Gr1high monocytes
that can rapidly respond to inflammatory and bacterial signals.
However, non-classical Gr1low monocytes make up 40%–50%
of the monocyte population in mice and 10% in humans
(Yona and Jung, 2010), and their functions are less well defined.
There are reports that they can migrate in atherosclerotic set-
tings (Nahrendorf et al., 2007) and can respond to viral and
TLR7/8 cues (Carlin et al., 2013b; Cros et al., 2010), but it is their
ability to patrol or survey the endothelial interface (Auffray et al.,
2007; Carlin et al., 2013b; Cros et al., 2010) that has become
widely recognized. Whether they can migrate and contribute to
tissue macrophages under steady-state conditions remains un-
clear. Unexpectedly, our data indicated that the behavior of
Gr1low monocytes was markedly altered within a high-TGRL
environment. We observed that in a high-TGRL environment,
Gr1low monocytes were depleted from the blood due to theirFigure 4. Tissue Accumulation of CD68+ Cells under P-407 Treatment
(A) Representative photomicrographs of CD68 staining (brown) of PLP fixed liver,
after PBS treatment for 28 days. Magnification as indicated.
(B) Quantitative analysis of CD68+ cells in (A) specimens showing accumulation of
expressed as mean percentage ± SE of the brown-stained area in a selected field
mean percentage ± SE of the brown-stained glomerular area/total glomerular are
mice per group. p value by unpaired t test is shown (*p < 0.05, **p < 0.01, and **
(C) Representative images of the Ki-67 staining (green) and CD68 (red) of the sectio
used as positive controls, and Ki-67+ cells are indicated with arrows. Scale bars
See also Figure S4.
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by a marked accumulation of CD68+ tissue macrophages in
the heart, liver, and kidney. Adoptive transfer experiments of
fluorescence-activated cell-sorted monocytes showed that,
under our experimental conditions, Gr1low monocytes were
able to extravasate. This finding, together with the results of
the Ki67 staining, ruled out the possibility that the increased
number of tissue macrophages was due to in situ proliferation,
as noted during inflammation (Davies et al., 2013).
We excluded the possibility that our findings were a direct
effect of P-407. Consistent with the findings in patients with
familial hypercholesterolemia (Mosig et al., 2009), we observed
a similar drop in the Gr1low monocytes in pre-atherosclerotic
Ldlr/ mice. Increased numbers of tissue macrophages have
previously been described in high-fat-fed models (Fink et al.,
2014; Lohmann et al., 2009). The production of monocytes is
finely tuned by BM stem cell precursors, which can be influ-
enced by dyslipidemia (Murphy et al., 2011). However, the
P-407-induced increase in TGRLs did not cause obvious
changes in the number of cMoPs or BM mature monocytes.
Moreover, splenectomy did not alter the response of the Gr1low
monocytes to the hyper-TGRL environment, excluding splenic
scavenging or extramedullary hematopoiesis as potential
mechanisms. Collectively, our observations point toward a
scenario where non-classical Gr1low monocytes specifically
respond to a rise in TGRL levels and, in the absence of overt
inflammatory cues, extravasate into peripheral tissue and or-
gans, contributing to the increased number of tissue CD68+
and F4/80+ macrophages. Our data, therefore, support the
notion of a more dynamic role of Gr1low monocytes in response
to dyslipidemia rather than being just intravascular house-
keepers or ‘‘blood macrophages’’ (Carlin et al., 2013b; Yona
and Jung, 2010). Whether these cells extravasate in response
to milder dyslipidemia or whether scavenging lipids in the tis-
sue is part of their housekeeping functions requires further
investigations.
Activation of Gr1low monocytes and their human counterparts
has been shown in murine lupus models and patients with SLE
(Amano et al., 2005; Cros et al., 2010; Nakatani et al., 2010; San-
tiago-Raber et al., 2009; Yoshimoto et al., 2007), suggesting that
Gr1low monocytes might contribute to tissue injury (Misharin
et al., 2014). In support of this, blockade of CX3CR1, which is
highly expressed on Gr1low monocytes, reduced monocyte
recruitment to the kidney and the resulting inflammation (Inoue
et al., 2005; Nakatani et al., 2010). Therefore, it is tempting to
speculate that in conditions where there is abnormal lipid meta-
bolism, such as chronic renal diseases, extravasated Gr1lowheart, and kidney sections after 7, 14, and 28 days of P-407 administration and
CD68+macrophages in the P-407-treated animals. For liver and heart, data are
/total field area (five different fields per section). For the kidney, data represent
a for 20 glomeruli per section. Values represent the mean ± SE of at least four
*p < 0.001).
ns (A) following 28 days of treatment with P-407 or PBS. Splenic sections were
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See also Figure S5.
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monocytes may convert into CD68+/F480+ macrophages
and contribute to tissue damage. Monocyte-specific lineage
reporters will be necessary to uncover the contribution of Gr1low
monocytes to tissue homeostasis and pathology under
hypertriglyceridemia.
We identified CCL4 as one of the potential molecules medi-
ating the changes in the distribution of blood monocytes during
hypertriglyceridemia. CCL4 is known to bind CCR5, a chemo-
kine receptor expressed by both monocyte subpopulations
(Tacke et al., 2007; Weber et al., 2000), a finding confirmed by
us. TGRL levels did not alter the monocyte phenotype or modu-
late CCR5 expression, making it an unlikely candidate for the
CCL4-mediated effect. However, administration of PT rectified
some of the drop in blood Gr1low monocytes, confirming that
a Gai chemokine-receptor axis was involved. CCL4 can be pro-
duced by different cell types, including macrophages (Maurer
and von Stebut, 2004). We found that CCL4 expression by
macrophages from the heart and liver was enhanced in the
hyper-TGRL environment. This suggests that a positive feed-
back loop may exist: foam cell formation, triggered by the
hyperlipidemia, initiates Gr1low monocyte recruitment that in
turn enhances foam cell formation, perpetuating the process.
Considering that CCL4 has been shown to be expressed by
macrophages in response to modified LDL (Wiesner et al.,
2010) and that its receptor, CCR5, mediates Gr1low recruitment
in atherosclerosis (Tacke et al., 2007), our data raise the possi-
bility that this chemokine may play a key role in the increased
CVD risk observed in chronic diseases associated with elevated
TGRLs.
In conclusion, our study demonstrates that high TGRL
levels alter monocyte subset distribution by promoting the
extravasation of the non-classical Gr1low subset. These findings
highlight the impact that an abnormal TGRL profile may have
on the intravascular and extravascular behavior of blood
monocytes.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6, C57BL/6.CD45.1, C57BL/6.LDLR-deficient (Ldlr/), and B6.129P-
Cx3cr1tm1Litt/J (Cx3cr1gfp/gfp) mice were used.
Poloxamer 407 Administration
Mice were injected i.p. with 10 mg Poloxamer 407 (Pluronic F-127, Sigma-
Aldrich) solution or PBS every second day.Figure 6. Chemokine Expression Triggered by P-407 Treatment
(A–D) The effect of P-407 on mRNA expression of chemokine/cytokine was analy
IL-6 to the housekeeping gene HPRT. Kidney, liver, and heart specimens from m
each time point.
(E) CCL4 and CCL2 mRNA expression relative to HPRT in CD45+F4/80+ sorted ti
treatment. Data are pooled from three animals per condition and representative
(F) Plasma concentrations of CCL4 and CCL2 after 7, 14, and 28 days of P-407
(G) Frequencies of Gr1high and Gr1low monocyte subsets in P-407-treated B6 m
represent mean ± SE, n = 3mice per group. Results are representative of three ind
and ***p < 0.001; unpaired t test). ND, nondetectable; ns, nonsignificant.
(H) Transwell migration assay. Fluorescence-activated cell-sorted Gr1high and Gr
recombinant mouse CCL4 (1–1,000 ng/ml) or PBS (0). The number of migrated cel
Data are mean ± SE. ***p < 0.001 (unpaired t test).
See also Figure S6.
Cell RepIn Vitro Experiments
PBMCs from B6 mice were cultured overnight in the presence of P-407 con-
centration ranging from 50 mg/ml to 10 mg/ml and then stained for propidium
iodide (PI) and Annexin V. PBMCs from B6 mice treated with PBS or P-407 for
28 days were stained for neutral lipid using the LipidTox kit (Invitrogen).
Cell Sorting and Adoptive Transfer Experiment
0.1 3 106 of fluorescence-activated cell-sorted Gr1lowGFPhigh or Gr1high
GFPlow monocytes from CD45.2 Cx3cr1gfp/gfp were injected intravenously
into congenic CD45.1 mice. Organs were collected 16 hr later.
PT
Mice treated for 10 days with P-407 were injected intravenously with 0.2 mg PT
(Tocris Bioscience) or PBS. One day later, monocytes subsets were assessed
by fluorescence-activated cell sorting analysis.
Splenectomy
Splenectomy was performed, and 4 weeks later, mice were treated with P-407
or PBS for 2 weeks. Monocyte subsets were then assessed by flow cytometry.
BrdU Pulsing
Three doses of BrdU (BD Pharmingen) were administered i.p. 3 hr apart. BrdU
incorporation in bloodmonocytes was assessed by bleeding themice 1, 3, and
5 days following BrdU injection.
Intravital Microscopy
Intravital microscopy was performed in mesentery and dermal ear microcircu-
lation of Cx3cr1gfp/+ and Cx3cr1gfp/gfp mice as previously described (Carlin
et al., 2013a). See Supplemental Experimental Procedures for details.
Transwell Migration Assay
Gr1low and Gr1high blood monocytes were sorted using Aria II FACS (Becton-
Dickson). 1 3 105 cells per well were seeded into 3-mm-pore transwell inserts
(Corning), using a chemoattractant gradient of 1–1,000 ng/ml of recombinant
mouse CCL4 or CCL2 (R&D Systems) or PBS and incubated at 37C for
2 hr. Transwell inserts were fixed and slides were imaged using a 103 objec-
tive on an Olympus BX51 widefield fluorescence microscope and nuclei were
manually counted from five fields.
Statistical Analysis
Comparisons between two groups were performed using two-tailed unpaired
Student’s t test or Mann-Whitney test as indicated in the figure legend. Statis-
tically significant is defined as p < 0.05. N for each experiment is given in the
figure or figure legends. *p < 0.05; **p < 0.01, ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.08.020.zed by RT-PCR. Relative expression of (A) CCL3, (B) CCL4, (C) CCL2, and (D)
ice treated with P-407 were compared with those from PBS-treated animals at
ssue macrophages from liver, heart, and kidney after 14 days of P-407 or PBS
of two independent experiments.
or PBS treatment. Values represent mean ± SE, n = 4 mice per group.
ice injected with PT or PBS. PBS-treated mice were used as controls. Values
ependent experiments. Significant p values are indicated (*p < 0.05, **p < 0.01,
1low monocytes were added to a transwell chamber for 2 hr in the presence of
ls per field was quantified (five fields per sample); pool of n = 3mice in triplicate.
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